Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure

Osimertinib is a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harbouring EGFR mutations. Pneumonitis is a severe adverse event (AE) related to osimertinib treatment which appears to be more frequent when associated with concurrent or previous anti-PD(L)...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Ecancermedicalscience
Prif Awduron: Harada, Guilherme, Santini, Fernando Costa, Canedo, Felipe Sales Nogueira Amorim, de Carvalho Oliveira, Leandro Jonata, Zuppani, Henrique Bortot, De Castro, Gilberto
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Cancer Intelligence 2019
Pynciau:
Case Report
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6834382/
https://ncbi.nlm.nih.gov/pubmed/31921341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2019.970
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg